{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:02:15Z","timestamp":1762642935930,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009663","name":"University Health Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["heartrhythmcasereports.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HeartRhythm Case Reports"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.hrcr.2023.10.033","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T02:52:38Z","timestamp":1699066358000},"page":"104-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Atypical atrial flutter: Exploring the relationship between ibrutinib chemotherapy and atrial myopathy"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5413-8070","authenticated-orcid":false,"given":"Nathan C.","family":"Denham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumaraswamy","family":"Nanthakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.T.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek P.","family":"Bhaskaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrcr.2023.10.033_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.hrcr.2023.10.033_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/ejh.13387","article-title":"Ibrutinib as initial therapy in chronic lymphocytic leukemia: a systematic review and meta-analysis","volume":"104","author":"Molica","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hrcr.2023.10.033_bib3","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrcr.2023.10.033_bib4","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.hrcr.2023.10.033_bib5","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.amjcard.2019.05.029","article-title":"Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy","volume":"124","author":"Fradley","year":"2019","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrcr.2023.10.033_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001049","article-title":"High incidence of atrial fibrillation in patients treated with ibrutinib","volume":"6","author":"Baptiste","year":"2019","journal-title":"Open Heart"},{"key":"10.1016\/j.hrcr.2023.10.033_bib7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bjh.14324","article-title":"Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study","volume":"175","author":"Thompson","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hrcr.2023.10.033_bib8","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.hrcr.2023.10.033_bib9","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrcr.2023.10.033_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101432","article-title":"Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation","volume":"30","author":"Yang","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.hrcr.2023.10.033_bib11","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hrcr.2023.10.033_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/circ.132.suppl_3.14587","article-title":"Abstract 14587: proarrhythmic effects of ibrutinib, a clinically approved inhibitor of Bruton\u2019s tyrosine kinase (BTK) used in cancer therapy","volume":"132","author":"Yang","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.hrcr.2023.10.033_bib13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3389\/fphys.2018.01380","article-title":"Calcium in the pathophysiology of atrial fibrillation and heart failure","volume":"9","author":"Denham","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.hrcr.2023.10.033_bib14","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.hrcr.2023.10.033_bib15","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.hrcr.2021.08.003","article-title":"Ibrutinib-associated atrial fibrillation treatment\u00a0with catheter ablation","volume":"7","author":"Kapoor","year":"2021","journal-title":"HeartRhythm Case Rep"}],"container-title":["HeartRhythm Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214027123002828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214027123002828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:35:43Z","timestamp":1761993343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214027123002828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2214027123002828"],"URL":"https:\/\/doi.org\/10.1016\/j.hrcr.2023.10.033","relation":{},"ISSN":["2214-0271"],"issn-type":[{"type":"print","value":"2214-0271"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical atrial flutter: Exploring the relationship between ibrutinib chemotherapy and atrial myopathy","name":"articletitle","label":"Article Title"},{"value":"HeartRhythm Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrcr.2023.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Heart Rhythm Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}